Anthem (ANTM) Dragging Feet on Sarepta's (SRPT) Exondys 51 is Likely Negotiating Tactic - Oppenheimer
Tweet Send to a Friend
Oppenheimer affirms Sarepta Therapeutics (Nasdaq: SRPT) at Outperform with a price target of $76 as Anthem said EXONDYS 51 wasn't ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
